Literature DB >> 20208565

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

S J Cooper1, H Zou, S N Legrand, L A Marlow, C A von Roemeling, D C Radisky, K J Wu, N Hempel, V Margulis, H W Tun, G C Blobe, C G Wood, J A Copland.   

Abstract

Loss of transforming growth factor-beta receptor III (TbetaRIII) correlates with loss of transforming growth factor-beta (TGF-beta) responsiveness and suggests a role for dysregulated TGF-beta signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TbetaRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TbetaRIII expression in human cells. We localize GATA3's binding to a 10-bp region of the TbetaRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TbetaRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TbetaRIII expression during ccRCC progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208565      PMCID: PMC3472631          DOI: 10.1038/onc.2010.64

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The changing natural history of renal cell carcinoma.

Authors:  A J Pantuck; A Zisman; A S Belldegrun
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

3.  GATA3 haplo-insufficiency causes human HDR syndrome.

Authors:  H Van Esch; P Groenen; M A Nesbit; S Schuffenhauer; P Lichtner; G Vanderlinden; B Harding; R Beetz; R W Bilous; I Holdaway; N J Shaw; J P Fryns; W Van de Ven; R V Thakker; K Devriendt
Journal:  Nature       Date:  2000-07-27       Impact factor: 49.962

4.  The GATA-3 gene is expressed during human kidney embryogenesis.

Authors:  M C Labastie; M Catala; J M Gregoire; B Peault
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

5.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Authors:  R J Motzer; M Mazumdar; J Bacik; W Berg; A Amsterdam; J Ferrara
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.

Authors:  John A Copland; Bruce A Luxon; Laila Ajani; Tapati Maity; Erica Campagnaro; Huiping Guo; Shauna N LeGrand; Pheroze Tamboli; Christopher G Wood
Journal:  Oncogene       Date:  2003-09-11       Impact factor: 9.867

7.  Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Authors:  Kaye L Stenvers; Melinda L Tursky; Kenneth W Harder; Nicole Kountouri; Supavadee Amatayakul-Chantler; Dianne Grail; Clayton Small; Robert A Weinberg; Andrew M Sizeland; Hong-Jian Zhu
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

8.  The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

Authors:  Hye Jin You; Tam How; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-03-26       Impact factor: 4.944

9.  Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta.

Authors:  Fernando Lopez-Casillas; Cecilia Riquelme; Yoshiaki Perez-Kato; M Veronica Ponce-Castaneda; Nelson Osses; Jose Esparza-Lopez; Gerardo Gonzalez-Nunez; Claudio Cabello-Verrugio; Valentin Mendoza; Victor Troncoso; Enrique Brandan
Journal:  J Biol Chem       Date:  2002-10-23       Impact factor: 5.157

10.  Loss of betaglycan expression in ovarian cancer: role in motility and invasion.

Authors:  Nadine Hempel; Tam How; Mei Dong; Susan K Murphy; Timothy A Fields; Gerard C Blobe
Journal:  Cancer Res       Date:  2007-05-23       Impact factor: 12.701

View more
  23 in total

1.  Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Authors:  Simon J Cooper; Christina A von Roemeling; Kylie H Kang; Laura A Marlow; Stefan K Grebe; Michael E Menefee; Han W Tun; Gerardo Colon-Otero; Edith A Perez; John A Copland
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

2.  PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.

Authors:  T Tao; X Yang; J Zheng; D Feng; Q Qin; X Shi; Q Wang; C Zhao; Z Peng; H Liu; W G Jiang; J He
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 3.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

4.  Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.

Authors:  Maria Panagopoulou; Makrina Karaglani; Ioanna Balgkouranidou; Eirini Biziota; Triantafillia Koukaki; Evaggelos Karamitrousis; Evangelia Nena; Ioannis Tsamardinos; George Kolios; Evi Lianidou; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

5.  Downregulation of microRNA-193-3p inhibits the progression of intrahepatic cholangiocarcinoma cells by upregulating TGFBR3.

Authors:  Yu-Long Han; Jia-Jun Yin; Jian-Jun Cong
Journal:  Exp Ther Med       Date:  2018-03-14       Impact factor: 2.447

6.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

7.  Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Authors:  Han W Tun; Laura A Marlow; Christina A von Roemeling; Simon J Cooper; Pamela Kreinest; Kevin Wu; Bruce A Luxon; Mala Sinha; Panos Z Anastasiadis; John A Copland
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

8.  Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma.

Authors:  Hongying Zheng; Xingqing Guo; Qingwu Tian; Hui Li; Yuanqi Zhu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

9.  Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.

Authors:  Lijoy K Mathew; Samuel S Lee; Nicolas Skuli; Shilpa Rao; Brian Keith; Katherine L Nathanson; Priti Lal; M Celeste Simon
Journal:  Cancer Discov       Date:  2013-11-04       Impact factor: 39.397

10.  Epigenetic Alteration by DNA Promoter Hypermethylation of Genes Related to Transforming Growth Factor-β (TGF-β) Signaling in Cancer.

Authors:  Sann Sanda Khin; Riko Kitazawa; Takeshi Kondo; Yuka Idei; Masayo Fujimoto; Ryuma Haraguchi; Kiyoshi Mori; Sohei Kitazawa
Journal:  Cancers (Basel)       Date:  2011-03-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.